Maintain pressure on reforms to protect NHSNICE approves psoriasis drug
NICE has approved adalimumab (Humira) for use as a treatment for chronic plaque psoriasis in adults.
It is currently the only fully human anti-TNF monoclonal antibody licensed for treating plaque psoriasis in the UK.
The drug was recommended by NICE for treating severe active ankylosing spondylitis in May, and it was approved in Scotland for psoriasis last month.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.